Cetus Corporation

Chiron Corporation

Leland Stanford Junior University

Cetus Oncology Corporation

Jack H Nunberg

Michael V Doyle

Thomas J White

Arthur D Newell

Thomas R Tice

Stanley N Cohen

Michael A Innis

Richard M Gilley

Terrance A Taforo

Annie C Chang

Chander P Bahl

Gary A Anderson

Robert T Schimke

Maninder Singh

Michael E Hudson

Jeffrey E Flatgaard

Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.

Human IL-2 as a vaccine adjuvant

Methods and compositions are provided for producing heterologous proteins in a micrcorganism host, particularly bacterium, without fusion to an endogenous protein. Particularly, the heterologous gene may be inserted into a vector comprising an endogenous gene, where the heterologous gene is preceded by a ribosomal binding site. A heterologous enzyme functional in a bacterial host is demonstrated.

Protein production at synthetic start site

Shipping fever, and other stress-related diseases in livestock, are treated by administration of a microencapsulated composition comprising IL-2 conjugated with a polyoxyethylene polymer, and mixed with a release-modulating amount of humen serum albumin. The microcapsules are administered parenterally, and release an effective amount of conjugated IL-2 continuously over a period of 14-30 days. These microcapsules are also effective in the treatment of cancer in mammals.

Controlled-release formulations of interleukin-2

Disclosed herein is a method of mitigating stress-related syndromes in livestock, such as shipping fever in cattle, by administration of human IL-2.

Method of controlling stress-related disease in livestock by

A gene having a DNA sequence complementary to that of the glucoamylase polypeptide mRNA from a fungal species, preferably Aspergillus awamori, is prepared. The mRNA is an approximately 2.2 kilobase poly A RNA obtained from fungal cells grown under conditions of glucoamylase induction. Reverse transcription of the mRNA provides a glucoamylase probe used to identify genomic digest fragments containing glucoamylase gene regions, which are sequenced to locate the introns and exons. The genomic fragments are spliced together to form a gene having a DNA sequence with altered or deleted introns which codes for fungal glucoamylase protein and is capable, when correctly combined with a cleaved DNA expression vector, of expressing a non-native protein having glucoamylase enzyme activity upon transformation of a host organism by the vector. The host is preferably bacteria or yeast. The transformed yeast host may be used to produce ethanol.

Glucoamylase CDNA

Polypeptides that are synthesized or expressed directly in microorganisms, include an amino acid sequence that is homologous to at least a portion of gp70 envelope protein of FELV, and are immunogens that elicit or prime a humoral response in cats and immunize cats against FeLV infection. The microbially produced polypeptides are exemplified by a group of E. coli-expressed fusion proteins that comprise a portion of the trp leader peptide and a portion of the trp E protein fused to various portions of a subgroup B gp70 envelope protein. The synthesized polypeptides are exemplified by polypeptides that are homologous to segments of the hydrophilic domains of the gp70 protein.

Feline leukemia virus vaccine

Feline leukemia virus vaccine plasmids for fusion protein of the gp70

A method is described for constructing double-stranded DNA using messenger RNA templates. DNA strands complementary to the templates are formed using a non-specific 3' hydroxy terminus primer. After separation, the DNA single strands are disabled from self priming by blocking the free 3' hydroxy. Primer segments are then provided complementary to a portion of the amino terminus-coding end of the desired single strands. These primer segments are then extended with a suitable polymerase to complete the complementary strands.

Method for using an amino-terminus DNA sequence to synthesize a specific

Growing community of inventors

Oakland, CA, United States of America

Jack H Nunberg